HealthPolitics

STAT+: Roche goes beyond licensing in deal with Chinese biotech

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/10/2026, 22:36:25 UTC.

Briefings

Bristol Myers Squibb achieved 51% risk reduction in multiple myeloma progression for Zenbexus via FDA accelerated approval in a Phase 3 trial. Simultaneously, Viatris acquired Pacira Biosciences for $1.65 billion. Roche partnered with Chinese startup Defand Therapeutics to discover new medicines, marking a shift from licensing existing candidates to developing new ones.

Key points

• Bristol Myers Squibb's Zenbexus reduced disease progression risk by 51% in a Phase 3 trial for multiple myeloma.
• Viatris acquired Pacira Biosciences for $1.65 billion to develop non-opioid pain therapies.

Context and limitations

This briefing covers only the two major recent events: Zenbexus's Phase 3 trial results and Viatris's acquisition. It does not include details on the specific discovery pipeline with Defand Therapeutics or any other biotech news.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 09/10/2026, 06:51:21 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidpwyrka4svajdefyhtxwf6hwcnpnu5rz3s7hmle3kw2fkaexteke